Exploring patient participation in reducing health-care-related safety risks

More documents

Recommendations

Info

Exploring patient participation in reducing health-care-related safety risks 90 Recommendation 5 – Pay specific attention to patients with a history of ADRs (health professional level) Significant attention should be paid to patients’ medication history, with a focus on previously experienced ADRs (including those involving OTC drugs and dietary supplements): these are crucial factors in safe pharmacotherapy. Recommendation 6 – Educate patients (patient level) There is a clear need for patient education, not only to improve health literacy, but also to facilitate communication with health care professionals on medicines prescribed and treatment courses followed (such as checklists like the Institute for Safe Medication Practices model, medicines memos and medicines lists). Doctors should articulate their expectations relating to patients bringing along their lists of medications with updated names and dosages, and patients should be made aware of the necessity of compiling a list of the medications they take. In addition, there is a need for patient education on the use of OTC drugs and the boundaries of safe self-care and treatment. Patients should be encouraged to use all potential sources of information about all medicines, including prescribed medicines, OTC drugs, dietary supplements and herbal remedies, as this contributes to medication safety and reduction of potentially related complications. Recommendation 7 – Involve patient organizations (patient level) Patient organizations need to play an active role as advocates and promoters of safetyculture changes. Enhancing appropriate developments includes raising awareness and strengthening knowledge relating to the potential and expected roles that patients can play in reducing medication-related safety risks, as well as providing empowerment and encouragement for the individuals and organizations in this participative process (Annex 6). References 1. Recommendation Rec(2006)7 of the Committee of Ministers to Member States on management of patient safety and prevention of adverse events in health care. (Adopted by the Committee of Ministers on 24 May 2006 at the 965th meeting of the Ministers’ Deputies.) Strasbourg, Council of Europe, 2006 (https://wcd.coe.int/ViewDoc. jsp?id=1005439&Site=CM, accessed 1 May 2012). 2. European Council recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (2009/0003 CNS). Brussels, Council of the European Union, 2009 (http://ec.europa.eu/health/ph_systems/ docs/patient_rec2009_en.pdf, accessed 1 May 2012). 3. Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare (2008/0142/COD). Strasbourg, European Parliament and Council, 2011 (http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF, accessed 1 May 2012). 4. Woroń J. Niekorzystne interakcje leków w farmakoterapii geriatrycznej [Unwanted drug interactions in geriatric pharmacotherapy]. Terapia, 2009, 1:1–7. 5. Polish Patients’ Federation [web site]. Warsaw, Federacja Pacjentów Polskich (http://www.federacjapp.pl/, accessed 1 May 2012).
Patient safety, rights and medication safety in primary care in Poland 6. Institute of Patients’ rights and Health Education [web site]. Warsaw, Fundacja Instytut Praw Pacjenta i Edukacji Zdrowotnej (http://www.prawapacjenta.eu/, accessed 1 May 2012). 7. Gurwitz JH et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association, 2003, 289(9):1107–1116. 8. Kostka-Trąbka E, Woroń J. Interakcje leków w praktyce klinicznej [Medicines interaction in clinical practice]. Warszawa, Doctors’ Publishing House, 2011. 9. Gallagher P, O’Mahony D. STOPP (screening tool of older persons’ potentially inappropriate prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age and Ageing, 2008, 37(6):673–679. Bibliography Woroń J et al. Bezpieczeństwo pacjenta w farmakoterapii bólu [The patient’s safety in pain pharmacotherapy]. Ból, 2009, 10:47–52. Coulter A. Paternalism or partnership? Patients have grown up – and there’s no going back. British Medical Journal, 1999, 319:719–720. Närhi U. Medicines information for consumers and patients – a review of the literature. Helsinki, Finnish National Agency for Medicines (Publication 1/2006; http://www. nam.fi/uploads/julkaisut/laakkeet/Drug_information_pdf, accessed 12 November 2006). Porebski G, Woroń J, Krzemieniecki K. Reakcje nadwrażliwości i desensytyzacja na leki w onkologii [Drug hypersensitivity reactions and desensitization in oncology]. Onkologia w Praktyce Klinicznej, 2009, 5:244–249. From compliance to concordance: towards shared goals in medicine taking. London, Royal Pharmaceutical Society of Great Britain, 1997. Smith J. Building a safer NHS for patients: improving medication safety. London, Department of Health, 2004. Woroń J et al. Samoleczenie bólu. IV Międzynarodowe Sympozjum “Postępy w leczeniu bólu”, Zakopane, 8–10 października 2009 [Pain self-medication. IV International Symposium “Advances in the treatment of pain”, Zakopane 8–10 October 2009]. Ból, 2009, 10:33–34. Woroń J, Filipczak-Bryniarska I, Dobrogowski J. Farmakoterapia bólu u pacjentów z czynnikami ryzyka [Pain pharmacotherapy in patients with risk factors]. Terapia, 2010, 11–12:5–10. Woroń J et al. Rzadkie niepożądane działania leków stosowanych w farmakoterapii bólu. IV Międzynarodowe Sympozjum “Postępy w leczeniu bólu”, Zakopane 8–10 października 2009 [Uncommonly adverse drug reactions in pain pharmacotherapy. IV International Symposium “Advances in the treatment of pain”, Zakopane 8–10 October 2009]. Ból, 2009, 10:34. 91
Page 1 and 2:
Exploring patient participation in
Page 3 and 4:
ABSTRACT Patients’ rights have be
Page 5 and 6:
iv Patient information: the link be
Page 7 and 8:
vi LIST OF TABLES, FIGURES AND BOXE
Page 9 and 10:
ACKNOWLEDGEMENTS The editors would
Page 11 and 12:
LIST OF ABBREVIATIONS ABHR alcohol-
Page 13 and 14:
FOREWORD Health is a social value a
Page 15 and 16:
ChApTER 1. pATIENTS’ RIGhTS AND p
Page 17 and 18:
Box 1 .1 . contd Reporting and Lear
Page 19 and 20:
The causal mechanisms through which
Page 21 and 22:
» be involved in routine monitorin
Page 23 and 24:
elationships within the complex env
Page 25 and 26:
ChApTER 2. pATIENTS’ RIGhTS AND p
Page 27 and 28:
CoE Recommendation 2006/7 of the Co
Page 29 and 30:
The 2005 United States act on patie
Page 31 and 32:
The right to participate in policy-
Page 33 and 34:
The right to participate in quality
Page 35 and 36:
» engaging with patient representa
Page 37 and 38:
hampered by the written and spoken
Page 39 and 40:
prevents misunderstandings and shap
Page 41 and 42:
Health care providers should nevert
Page 43 and 44:
Recommendation 7 - Encourage the av
Page 45 and 46:
20. Constitution of the World Healt
Page 47 and 48:
ChApTER 3. pATIENT pARTICIpATION IN
Page 49 and 50:
awareness of the sociomedical burde
Page 51 and 52:
Patient participation in hand hygie
Page 53 and 54: Patient participation in hand hygie
Page 61 and 62: Blood transfusion safety in France:
Page 65 and 66: Box 4 .1 . Definitions of adverse e
Page 67 and 68: Fig . 4 .4 . Distribution of advers
Page 73 and 74: The heterogeneity of situations and
Page 83 and 84: Fig . 4 .12 . Patients’ response
Page 91 and 92: Patient safety, rights and medicati
Page 97 and 98: Fig . 5 .3 . Frequency with which d
Page 103: Patient safety, rights and medicati
Page 107 and 108: ChApTER 6. pATIENT pARTICIpATION IN
Page 109 and 110: Patient participation in elective s
Page 111 and 112: e desirable to have a special statu
Page 117 and 118: inspections of surgical services to
Page 133 and 134: » being involved in monitoring and
Page 135 and 136: Other studies on patient attitudes
Page 137 and 138: Information about patients’ exper
Page 139 and 140: available evidence suggests that in
Page 141 and 142: Adverse events Respondents from the
Page 143 and 144: Feeling safe Five per cent of hospi
Page 145 and 146: probability proportional to populat
Page 147 and 148: care professionals’ and patients
Page 149 and 150: group recommends that patient invol
Page 151 and 152: 13. Hibbard JH et al. Can patients
Page 153 and 154: 52. Triemstra M et al. Measuring cl
Page 155 and 156:
2009 (http://www.bradfordresearch.n
Page 157 and 158:
of a small-scale patient survey add
Page 159 and 160:
Box 8 .2 . Curricula and CME Chapte
Page 161 and 162:
is provided through interaction of
Page 163 and 164:
Box 8 .4 . Patient education Chapte
Page 165 and 166:
ANNEX 1. QUOTATIONS FROM INTERNATIO
Page 167 and 168:
(2) When designing adverse event re
Page 169 and 170:
17) If yes, do you think this was m
Page 171 and 172:
Box A3 .1 . Reporting procedure Pat
Page 173 and 174:
Box A3 .2 . contd Haemosiderosis Ha
Page 175 and 176:
ANNEX 4. pATIENT QUESTIONNAIRE ABOU
Page 177 and 178:
ANNEX 6. WhO pATIENT SAFETY pROGRAM
Page 179 and 180:
especially those in intensive care.
Page 181 and 182:
ANNEX 7. hANDOVER pROjECT Paul Bara
Page 183 and 184:
(a) Provide new insight into the ro
Page 185 and 186:
Johnson J, Barach P. Handovers of p
Page 187 and 188:
Enhancing the patients’ role in p
Page 189 and 190:
Enhancing the patients’ role in p
show all

Exploring patient participation in reducing health-care-related safety risks

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?